Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 801–900 of 1,003
Historical perspectives on myelodysplastic syndromes
Steensma, D. P. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.08.007 · Cited by 30
Giannopoulos, K., Jamroziak, K., Usnarska‐Zubkiewicz, L., Dytfeld, D., Jurczyszyn, A. J., Walewski, J. A., Lech‐Marańda, E., Walter‐Croneck, A., Pieńkowska‐Grela, B., Wróbel, T., et al. (2018) · Acta Haematologica Polonica · doi:10.2478/ahp-2018-0024 · Cited by 30
Human teratogens and genetic phenocopies. Understanding pathogenesis through human genes mutation
Cassina, M., Cagnoli, G. A., Zuccarello, D., Gianantonio, E. D., & Clementi, M. (2016) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2016.09.011 · Cited by 30
Beedie, S., Huang, P. A., Harris, E. M., Strope, J. D., Mahony, C. B., Chau, C. H., Vargesson, N., & Figg, W. D. (2020) · The FASEB Journal · doi:10.1096/fj.201903060rr · Cited by 30
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 30
An IMiD-induced SALL4 degron system for selective degradation of target proteins
Yamanaka, S., Shoya, Y., Matsuoka, S., Nishida-Fukuda, H., Shibata, N., & Sawasaki, T. (2020) · Communications Biology · doi:10.1038/s42003-020-01240-5 · Cited by 29
Patil, A., Manzano, M., & Gottwein, E. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019031732 · Cited by 29
Dai, Q., Huang, J., Qiu, X., Luo, X., Wang, D., & Li, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00036 · Cited by 29
Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
Vicente, A. T. S., Moura, S. P. S. P., & Salvador, J. A. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01598-9 · Cited by 29
Novel Generation of Agents With Proven Clinical Activity in Multiple Myeloma
Mateos, M., Ocio, E. M., & Miguel, J. F. S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.005 · Cited by 29
Pharmacogenetics of treatments for inflammatory bowel disease
Lucafò, M., Franca, R., Selvestrel, D., Curci, D., Pugnetti, L., Decorti, G., & Stocco, G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551876 · Cited by 29
Ubiquitin-dependent proteasomal degradation of AMPK gamma subunit by Cereblon inhibits AMPK activity
Yang, S., Jeon, S., Nguyen, T. V., Deshaies, R. J., Park, C., & Lee, K. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118729 · Cited by 29
ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment
Liu, J., Hideshima, T., Xing, L., Wang, S., Zhou, W., Samur, M., Sewastianik, T., Ogiya, D., An, G., Gao, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg2697 · Cited by 29
Hanel, W. G., & Epperla, N. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01113-2 · Cited by 29
Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
Costacurta, M., He, J., Thompson, P. E., & Shortt, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111185 · Cited by 29
Functional Validation of Osteoporosis Genetic Findings Using Small Fish Models
Kague, É., & Karasik, D. (2022) · Genes · doi:10.3390/genes13020279 · Cited by 29
Targeted protein degradation as an antiviral approach
Chakravarty, A., & Yang, P. L. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105480 · Cited by 29
Eyre, T. A., & Riches, J. C. (2023) · Cancers · doi:10.3390/cancers15092596 · Cited by 29
Bagka, M., Choi, H., Héritier, M., Schwaemmle, H., Pasquer, Q. T. L., Braun, S. M. G., Scapozza, L., Wu, Y., & Hoogendoorn, S. (2023) · Nature Communications · doi:10.1038/s41467-023-39657-1 · Cited by 29
PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
Mancarella, C., Morrione, A., & Scotlandi, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216346 · Cited by 29
Zhang, J., Chen, X., Chen, C., Li, F., Song, X., Liu, C., Liao, K., Su, M.-Y., Tan, C. S. H., Fang, L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00208 · Cited by 29
How lenalidomide is changing the treatment of patients with multiple myeloma
Dimopoulos, M. A., Terpos, E., & Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.013 · Cited by 29
Protein ubiquitination in lymphoid malignancies
Yang, Y., & Staudt, L. M. (2014) · Immunological Reviews · doi:10.1111/imr.12247 · Cited by 29
Madan, R. A., Karzai, F. H., Ning, Y. M., Adesunloye, B. A., Huang, X., Harold, N., Couvillon, A., Chun, G., Cordes, L. M., Sissung, T. M., et al. (2016) · British Journal of Urology · doi:10.1111/bju.13412 · Cited by 29
Eisenberg‐Lerner, A., Ciechanover, A. J., & Merbl, Y. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216651732 · Cited by 29
Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads
Jain, J., Jain, S. K., Walker, L., & Tekwani, B. L. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0147-4 · Cited by 29
Bhutani, M., Zhang, Q., Friend, R. N., Voorhees, P. M., Druhan, L. J., Barlogie, B., Sonneveld, P., Morgan, G. J., Symanowski, J. T., Avalos, B. R., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30143-6 · Cited by 29
Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
Zhang, J., Chen, P., Zhu, P., Zheng, P., Wang, T., Wang, L., Xu, C., Zhou, J., & Zhang, H. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103817 · Cited by 29
Advancements in Assay Technologies and Strategies to Enable Drug Discovery
Busby, S. A., Carbonneau, S., Concannon, J. B., Dumelin, C. E., Lee, Y., Numao, S., Renaud, N., Smith, T. M., & Auld, D. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00495 · Cited by 29
Into the Fray! A Beginner's Guide to Medicinal Chemistry
Veale, C. G. L. (2021) · ChemMedChem · doi:10.1002/cmdc.202000929 · Cited by 29
T herapeutic targeting of chromatin: status and opportunities
Siklos, M. I., & Kubicek, S. (2021) · FEBS Journal · doi:10.1111/febs.15966 · Cited by 29
Cassidy, K. B., & Zhao, H. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00330 · Cited by 29
Zhang, H., Ren, J.-X., Kang, Y.-L., Bo, P., Liang, J., Ding, L., Kong, W.-B., & Zhang, J. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2017.04.005 · Cited by 29
Ma, X., Wang, X., Chen, F., Zou, W., Ren, J., Xin, L., He, P., Liang, J., Xu, Z., Dong, C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00131 · Cited by 28
Mercurio, A., Sharples, L., Corbo, F., Franchini, C., Vacca, A., Catalano, A. A., Carocci, A., Kamm, R. D., Pavesi, A., & Adriani, G. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00349 · Cited by 28
Tachita, T., Kinoshita, S., Ri, M., Aoki, S., Asano, A. T., Kanamori, T., Yoshida, T., Totani, H., Ito, A., Kusumoto, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14352 · Cited by 28
Alnefaie, A., & Albogami, S. M. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.024 · Cited by 28
The Role of Cullin-RING Ligases in Striated Muscle Development, Function, and Disease
Blondelle, J., Biju, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217936 · Cited by 28
Misiewicz-Krzemińska, I., Ramón, C. D., Corchete, L. A., Krzemiński, P., Rojas, E. A., Isidro, I. M., García‐Sánz, R., Martínez‐López, J., Oriol, A., Bladé, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002711 · Cited by 28
The E3 ubiquitin ligase Cul4b promotes CD4+ T cell expansion by aiding the repair of damaged DNA
Dar, A. A., Sawada, K., Dybas, J. M., Moser, E. K., Lewis, E. L., Park, E., Fazelinia, H., Spruce, L. A., Ding, H., Seeholzer, S. H., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001041 · Cited by 28
McCurdy, A. B. R., & Lacy, M. Q. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713480155 · Cited by 28
Wang, J., Nie, Y., Li, Y., Hou, Y., Zhao, W., Deng, J., Wang, P. G., & Bai, G. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b04439 · Cited by 27
Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs
Fuchs, O. (2018) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x18666180522073855 · Cited by 28
The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents
Coll-Martínez, B., Delgado, A., & Crosas, B. (2020) · Molecules · doi:10.3390/molecules25245956 · Cited by 28
Chernobrovkin, A. L., Cázares-Körner, C., Friman, T., Caballero, I. M., Amadio, D., & Molina, D. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220984372 · Cited by 29
Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Rodrigues, D. A., Roe, A. J., Griffith, D. M., & Chonghaile, T. N. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211015092047 · Cited by 28
Oekelen, O. V., Amatangelo, M. D., Guo, M., Upadhyaya, B., Cribbs, A. P., Kelly, G., Patel, M., Kim‐Schulze, S., Flynt, E., Laganà, A., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101584 · Cited by 27
Zhou, Y., Garrigues, S. L., Villemure, E., Ishisoko, N., Nguyen, H. Q., Hamidi, N. K., Vogt, R., Wang, Y., Blake, R. A., Rudolph, J., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.4c00445 · Cited by 27
Benchmarking Cofolding Methods for Molecular Glue Ternary Structure Prediction
Liao, Y., Zhu, J., Xie, J., Lai, L., & Pei, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c01860 · Cited by 27
Han, J., Fu, J., Sun, J., Hall, D. R., Yang, D., Blatz, D. J., Houck, K. A., Ng, C. A., Doering, J. A., LaLone, C. A., et al. (2021) · Environmental Science & Technology · doi:10.1021/acs.est.1c00509 · Cited by 27
Takwale, A. D., Kim, E. Y., Jang, Y., Lee, D.-H., Kim, S., Choi, Y., Kim, J. H., Lee, D. Y., Kim, Y., Lee, S. M., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105923 · Cited by 27
Antermite, D., Friis, S. D., Johansson, J. R., Putra, O. D., Ackermann, L., & Johansson, M. J. (2023) · Nature Communications · doi:10.1038/s41467-023-43789-9 · Cited by 27
Park, H., & Park, S. B. (2019) · Chemical Science · doi:10.1039/c8sc05465g · Cited by 27
Efficacy of Thalidomide in Discoid Lupus Erythematosus: Insights into the Molecular Mechanisms
Domingo, S., Solé, C., Moliné, T., Fábrega, B. F., Ordi‐Ros, J., & Cortés-Hernández, J. (2020) · Dermatology · doi:10.1159/000508672 · Cited by 27
Nayak, S., Norris, J. D., Ammirante, M., Rychak, E., Wardell, S. E., Liao, D., Toyama, B., Kandimalla, R., Christoforou, A., Tsuji, T., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0471 · Cited by 26
Veenbergen, S., van Leeuwen, M. A., Driessen, G. J. A., Kersseboom, R., de Ruiter, L. F., Raatgeep, R. C., Lindenbergh-Kortleve, D. J., Simons-Oosterhuis, Y., Biermann, K., Halley, D. J. J., et al. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001559 · Cited by 26
Probing ubiquitin and SUMO conjugation and deconjugation
Ovaa, H., & Vertegaal, A. C. O. (2018) · Biochemical Society Transactions · doi:10.1042/bst20170086 · Cited by 26
Yang, Y., & Chen, L. (2019) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000145 · Cited by 26
Targeting phosphatases: From molecule design to clinical trials
Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 26
Targeted Therapy of Multiple Myeloma
Dolloff, N. G., & Talamo, G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_9 · Cited by 26
Investigative safety science as a competitive advantage for Pharma
Moggs, J. G., Moulin, P., Pognan, F., Brees, D., Leonard, M., Busch, S., Cordier, A., Heard, D. J., Kammuller, M. E., Merz, M., et al. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.693914 · Cited by 26
Wang, X., Shen, Y., Li, S., Lv, M., Zhang, X., Yang, J., Wang, F., & Yang, J. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2724 · Cited by 26
Ko, J. R., Seo, D. Y., Park, S. H., Kwak, H. B., Kim, M. G., Ko, K. S., Rhee, B. D., & Han, J. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.009 · Cited by 26
Establishment of a novel non-integrated human pluripotent stem cell-based gastruloid modelPreprint
Yuan, G., Wang, J., Liu, Z., Chen, M., Zhu, P., Zhang, H., Hu, Z., Cui, Y., Yuan, Y., & Sha, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.28.546720 · Cited by 26
Discovery of a VHL molecular glue degrader of GEMIN3 by Picowell RNA-seqPreprint
Bushman, J. W., Deng, W., Samarasinghe, K. T. G., Liu, H., Li, S., Vaish, A., Golkar, A., Ou, S., Ahn, J., Harijan, R. K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.644003 · Cited by 26
Hirano, M., Imai, Y., Kaito, Y., Murayama, T., Sato, K., Ishida, T., Yamamoto, J., Ito, T., Futami, M., Ri, M., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01909-7 · Cited by 25
Self-citationDegradome analysis to identify direct protein substrates of small-molecule degraders
Jochem, M., Schrempf, A., Wagner, L.-M., Segal, D., Cisneros, J., Ng, A., Winter, G. E., & Krijgsveld, J. (2025) · Cell Chemical Biology · doi:10.1016/j.chembiol.2024.10.007 · Cited by 25
Fu, S.-J., Hu, M., Peng, Y.-J., Fang, H.-Y., Hsiao, C.-T., Chen, T., Jeng, C., & Tang, C. (2020) · Cells · doi:10.3390/cells9061332 · Cited by 25
Discovering new biology with drug-resistance alleles
Freedy, A. M., & Liau, B. B. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00865-9 · Cited by 25
Crbn-based molecular Glues: Breakthroughs and perspectives
An, J., & Zhang, X. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117683 · Cited by 25
Cereblon inhibits proteasome activity by binding to the 20S core proteasome subunit beta type 4
Lee, K. M., Lee, J., & Park, C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.09.108 · Cited by 25
Inoue, A., Nishimura, Y., Matsumoto, N., Umemoto, N., Shimada, Y., Maruyama, T., Kayasuga, K., Morihara, M., Katagi, J., Shiroya, T., et al. (2016) · Fundamental Toxicological Sciences · doi:10.2131/fts.3.79 · Cited by 25
Advancing our Understanding of Ubiquitination Using the Ub-Toolkit
Witting, K. F., Mulder, M. P. C., & Ovaa, H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.002 · Cited by 25
Targeting Protein–Protein Interactions in the Ubiquitin–Proteasome Pathway
Gaczynska, M. E., & Osmulski, P. A. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.09.001 · Cited by 25
Willenbacher, W., Seeber, A., Steiner, N., Willenbacher, E., Gatalica, Z., Swensen, J. J., Kimbrough, J., & Vranić, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072087 · Cited by 25
Jeng, C., Fu, S.-J., You, C.-Y., Peng, Y.-J., Hsiao, C.-T., Chen, T., & Tang, C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00076 · Cited by 25
Targeted modulation of E3 ligases using engineered ubiquitin variants
LeBlanc, N., Mallette, E., & Zhang, W. (2020) · FEBS Journal · doi:10.1111/febs.15536 · Cited by 25
Hu, Z., Li, H., Wang, X., Ullah, K., & Xu, G. (2020) · Journal of Proteomics · doi:10.1016/j.jprot.2020.103996 · Cited by 25
Abouelnazar, F. A., Zhang, X., Zhang, J., Wang, M., Yu, D., Zang, X., Zhang, J., Li, Y., Xu, J., Yang, Q., et al. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02985-9 · Cited by 24
Targeted degradation of CDK9 potently disrupts the MYC-regulated network
Toure, M. A., Motoyama, K., Xiang, Y., Urgiles, J., Kabinger, F., Koglin, A.-S., Iyer, R. S., Gagnon, K., Kumar, A., Ojeda, S., et al. (2025) · Cell chemical biology · doi:10.1016/j.chembiol.2025.03.001 · Cited by 24
Cellular parameters shaping pathways of targeted protein degradation
Cardno, A., Kennedy, B., & Lindon, C. (2025) · Communications Biology · doi:10.1038/s42003-025-08104-w · Cited by 24
Targeted Destruction of S100A4 Inhibits Metastasis of Triple Negative Breast Cancer Cells
Ismail, T. M., Crick, R. G., Du, M., Shivkumar, U., Carnell, A. J., Barraclough, R., Wang, G., Cheng, Z., Yu, W., Platt-Higgins, A. M., et al. (2023) · Biomolecules · doi:10.3390/biom13071099 · Cited by 24
Mabrouk, R. R., Abdallah, A. E., Mahdy, H. A., El-Kalyoubi, S. A., Kamal, O., Abdelghany, T. M., Zayed, M. F., Alshaeri, H. K., Alasmari, M. M., & El‐Zahabi, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512416 · Cited by 24
Facilitating the development of molecular glues: Opportunities from serendipity and rational design
Jiang, W., Jiang, Y., Luo, Y., Qiao, W., & Yang, T. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115950 · Cited by 24
Nutt, M. J., & Stewart, S. G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104010 · Cited by 24
Risseeuw, M., Clercq, D. J. H. D., Lievens, S., Hillaert, U., Sinnaeve, D., den Broeck, F. V., Martins, J. C., Tavernier, J. H., & Calenbergh, S. V. (2013) · ChemMedChem · doi:10.1002/cmdc.201200493 · Cited by 24
Protein Network Interacting with BK Channels
Kim, H., & Oh, K. H. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.03.003 · Cited by 24
BSG and MCT1 Genetic Variants Influence Survival in Multiple Myeloma Patients
Łacina, P., Butrym, A. K., Mazur, G. J., & Bogunia‐Kubik, K. (2018) · Genes · doi:10.3390/genes9050226 · Cited by 24
Cho, J., Horikawa, Y., Enya, M., Takeda, J., Imai, Y., Imai, Y., Handa, H., & Imai, T. (2020) · Communications Biology · doi:10.1038/s42003-020-01226-3 · Cited by 24
Self-citationStructure driven compound optimization in targeted protein degradation
Leissing, T. M., Luh, L. M., & Cromm, P. M. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.11.005 · Cited by 24
Furukawa, T., Sakamoto, N., Suzuki, M., Kimura, M., Nagasawa, H., & Sakuda, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135031 · Cited by 24
The Vital Role of Proteomics in Characterizing Novel Protein Degraders
Zhang, A. X., Cassidy, K. B., Dahl, G., Moreau, K., Pachl, F., & Zuhl, A. M. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220985776 · Cited by 23
Lin, W., & Chen, T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00032 · Cited by 23
Hsueh, S., Luo, W., Tweedie, D., Kim, D. S., Kim, Y. K., Hwang, I., Gil, J.-E., Han, B., Chiang, Y. H., Selman, W. R., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00042 · Cited by 23
Steiner, A., Krieger, J., Jones, R. C., Böse, D., Wang, Y., Eggenweiler, H., Williams, J. D., & Kappe, C. O. (2022) · ChemCatChem · doi:10.1002/cctc.202201184 · Cited by 23
Wang, L., Li, F., Ma, X., Cang, Y., & Bai, F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01033 · Cited by 23
Vargesson, N., Hooper, G., Giddins, G. E. B., Hunter, A., Stirling, P., & Lam, W. (2023) · Journal of Hand Surgery (European Volume) · doi:10.1177/17531934231177425 · Cited by 23
Jiang, Y., Ni, S., Xiao, B., & Jia, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.07.019 · Cited by 23
Szewczyk, S. M., Verma, I., Edwards, J. T., Weiss, D. R., & Chekler, E. L. P. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01872 · Cited by 23
Chemoproteomics Identifies State-Dependent and Proteoform-Selective Caspase-2 Inhibitors
Castellón, J. O., Ofori, S., Burton, N. R., Julio, A. R., Turmon, A. C., Armenta, E., Sandoval, C., Boatner, L. M., Takayoshi, E. E., Faragalla, M., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.3c12240 · Cited by 23
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.